Paula Clemens, MD
Neurology · Pittsburgh, PANPI 1447222096
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $69,895 of the $86,957 with a category attached, or 80.4%. NS Pharma, Inc. accounts for 71.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $60,206 and has fallen 95.6% since, to $2,677 in 2025. Among neurology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 66 payments — averaging $1317.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NS Pharma, Inc.$62K
- F. Hoffmann-la Roche AG$12K
- Sanofi$7K
- Spark Therapeutics, Inc.$4K
- Amicus Therapeutics, Inc.$1K
- Pfizer$382
- plus $407 from 3 others
Across 248 payments — averaging $8211.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$961K
- Amicus Therapeutics, Inc.$652K
- NS Pharma, Inc.$316K
- Spark Therapeutics, Inc.$63K
- Sanofi US Services Inc.$43K
- Aurinia Pharma U.S., Inc.$845
What the payments were for
- Consulting fees$69,89580%
- Speaking & faculty fees$1,5512%
- Travel & lodging$12,77515%
- Food & beverage$2,7353%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NS Pharma, Inc. | 13 | $61,807 |
| F. Hoffmann-la Roche AG | 4 | $12,391 |
| Sanofi | 38 | $6,572 |
| Spark Therapeutics, Inc. | 3 | $4,026 |
| Amicus Therapeutics, Inc. | 3 | $1,371 |
| Pfizer | 1 | $382 |
| Catalyst Pharmaceuticals, Inc. | 1 | $273 |
| Sarepta Therapeutics, Inc. | 2 | $111 |
| Argenx US, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VILTEPSO$60,206
- Non-Covered Product$12,391
- Viltolarsen (NS-065/NCNP-01)$1,601
- LUMIZYME$1,477
- NEXVIAZYME$1,361
- NO PRODUCT DISCUSSED$620
- AGAMREE$273
- FIRDAPSE$273
How this compares
$86,957 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 32 | $397 |
| Nortriptyline Hcl | 15 | $256 |
| Carbamazepine ErCarbamazepine | 12 | $201 |
| Baclofen | 12 | $70 |
Paid to pharmacies, not to this prescriber.
Other neurology in Pittsburgh
- Anoopum GuptaPittsburgh$592K
- Thomas ScottPittsburgh$476K
- James ValerianoPittsburgh$416K
- Amber van LaarPittsburgh$413K
- Andrea SynowiecPittsburgh$386K
- Dolores Dominguez SantamariaPittsburgh$265K
- Heather MouryPittsburgh$186K
- Troy DesaiPittsburgh$174K
- Richard KasdanPittsburgh$172K
- David LobasPittsburgh$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.